In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Due to its relatively slow clinical progression, B cell chronic lymphocytic leukemia (B-CLL) is classically described as a disease of accumulation rather than proliferation. However, evidence for various forms of clonal evolution suggests that B-CLL clones may be more dynamic than previously assumed. We used a nonradioactive, stable isotopic labeling method to measure B-CLL cell kinetics in vivo. Nineteen patients drank an aliquot of deuterated water (2H2O) daily for 84 days, and 2H incorporation into the deoxyribose moiety of DNA of newly divided B-CLL cells was measured by gas chromatography/mass spectrometry, during and after the labeling period. Birth rates were calculated from the kinetic profiles. Death rates were defined as the difference between calculated birth and growth rates. These analyses demonstrated that the leukemic cells of each patient had definable and often substantial birth rates, varying from 0.1% to greater than 1.0% of the entire clone per day. Those patients with birth rates greater than 0.35% per day were much more likely to exhibit active or to develop progressive disease than those with lower birth rates Thus, B-CLL is not a static disease that results simply from accumulation of long-lived lymphocytes. Rather, it is a dynamic process composed also of cells that proliferate and die, often at appreciable levels. The extent to which this turnover occurs has not been previously appreciated. A correlation between birth rates and disease activity and progression appears to exist, which may help identify patients at risk for worsening disease in advance of clinical deterioration.

[1]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[2]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[3]  G. Guida,et al.  The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. , 2003, Blood.

[4]  Arthur Weiss,et al.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.

[5]  J. McCune,et al.  Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[7]  T. Kipps,et al.  Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Oscier,et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.

[9]  A. Tefferi,et al.  Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia , 2001, British journal of haematology.

[10]  M Chilosi,et al.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[11]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[12]  P. Ghia,et al.  The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. , 2000, Advances in cancer research.

[13]  S. Pileri,et al.  The pathologist's view point. Part I--indolent lymphomas. , 2000, Haematologica.

[14]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[15]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[16]  T J Hamblin,et al.  B-cell chronic lymphocytic leukemia: a bird of a different feather. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Rassenti,et al.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.

[18]  M. Hellerstein,et al.  Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose: studies in vitro, in animals, and in humans. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[20]  S. E. Brodie New York, New York, USA , 1996 .

[21]  R. Hoffman,et al.  Hematology: Basic Principles and Practice , 1995 .

[22]  P. Isaacson,et al.  Proliferation centres in B‐cell malignant lymphoma, lymphocytic (B‐CLL): an immunophenotypic study , 1994, Histopathology.

[23]  G. Marti,et al.  Evolution of leukemic heterogeneity of human B-CLL lymphocytes between and within patients. , 1992, Current topics in microbiology and immunology.

[24]  S. Chevret,et al.  B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. , 1991, Blood.

[25]  W. Plunkett,et al.  Metabolism and action of purine nucleoside analogs. , 1991, Pharmacology & therapeutics.

[26]  S. Molica,et al.  Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia , 1987, Cancer.

[27]  Ciril Rozman,et al.  Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.

[28]  P. Dörmer,et al.  Chronic lymphocytic leukemia: a proliferative or accumulative disorder? , 1983, Leukemia research.

[29]  K. Nilsson,et al.  3H-thymidine uptake in chronic lymphocytic leukaemia cells. , 2009, Scandinavian journal of haematology.

[30]  E. Cronkite,et al.  Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia. , 1979, Blood.

[31]  I. Chanarin,et al.  Studies in chronic lymphocytic leukaemia. The kinetics of 51Cr-labelled lymphocytes. , 2009, Scandinavian journal of haematology.

[32]  L. Terenius,et al.  Biochemical characteristics of chronic lymphocytic leukaemia. Glucocorticoid receptors, B and T lymphocyte surface markers, concanavalin A-induced agglutination and thymidine incorporation. , 2009, Scandinavian journal of haematology.

[33]  L. Debusscher,et al.  Cell kinetics in chronic lymphocytic leukaemia (CLL). , 1977, Clinics in haematology.

[34]  P. Schick,et al.  Kinetics of lymphocytes in chronic lymphocytic leukemia: studies using continuous 3H-thymidine infusion in two patients. , 1973, Blood.

[35]  J. Frühling,et al.  Kinetics of lymphocytes in chronic lymphocytic leukemia. I. Equilibrium between blood and a "readily accessible pool". , 1973, Blood.

[36]  E. Cronkite,et al.  Lymphocyte kinetics in chronic lymphocytic leukaemia (CLL) studied by ECIB. , 1969, British journal of haematology.

[37]  S. Perry,et al.  Studies of leukocyte kinetics in chronic lymphocytic leukemia. , 1968, Blood.

[38]  W. Dameshek Special Article: Chronic Lymphocytic Leukemia—an Accumulative Disease of Immunologically Incompetent Lymphocytes , 1967 .

[39]  W. Dameshek Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes. , 1967, Blood.